OVERVIEW

GHRP-6 (5 mg × 10) and CJC-1295 no DAC (5 mg × 10) is a peptide combination commonly used in research to stimulate growth hormone (GH) release. GHRP-6 is a growth hormone-releasing peptide (GHRP) that acts by binding to the ghrelin receptor (GHS-R1a), triggering the release of GH from the pituitary gland. One of its key effects is increasing insulin-like growth factor-1 (IGF-1), which plays a role in promoting muscle growth, tissue repair, and fat metabolism. CJC-1295 no DAC, a synthetic growth hormone-releasing hormone (GHRH) analog, also stimulates GH release but does so via the GHRH receptor. Unlike CJC-1295 with DAC (Drug Affinity Complex), the no DAC variant has a shorter half-life, promoting more natural, pulsatile GH secretion. The combination of these two peptides enhances GH release through two distinct pathways: one via ghrelin receptor activation (GHRP-6) and the other through GHRH receptor activation (CJC-1295 no DAC), making it a popular blend in research studies focused on metabolic function, recovery, and regenerative medicine.

Despite its research applications, this peptide combination is not FDA-approved for therapeutic use in humans. Most data supporting its biological effects comes from animal studies, in vitro experiments, and small human trials, while safety, dosing, and long-term effects in humans remain poorly understood. Products containing these peptides are often labeled for research use only and may vary in purity, concentration, and quality. Individuals interested in GH modulation or metabolic research should rely on evidence-based treatments and consult healthcare professionals before using experimental peptides outside of controlled research environments.